<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.433">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Estimands SME network">

<title>Oncology Estimand WG - New-anti lymphoma treatment (NALT) as intercurrent event for PFS in lymphoma</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>

  <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">Oncology Estimand WG</span>
    </a>
  </div>
            <div id="quarto-search" class="" title="Search"></div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-about" role="button" data-bs-toggle="dropdown" aria-expanded="false" rel="" target="">
 <span class="menu-text">About</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-about">    
        <li>
    <a class="dropdown-item" href="./index.html" rel="" target="">
 <span class="dropdown-text">About</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./updates.html" rel="" target="">
 <span class="dropdown-text">Updates of this page</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./history.html" rel="" target="">
 <span class="dropdown-text">History</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./scope.html" rel="" target="">
 <span class="dropdown-text">Scope</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./status.html" rel="" target="">
 <span class="dropdown-text">Status</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./organization.html" rel="" target="">
 <span class="dropdown-text">Organization</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./collaborations.html" rel="" target="">
 <span class="dropdown-text">Collaborations</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./achievements.html" rel="" target="">
 <span class="dropdown-text">Achievements per year</span></a>
  </li>  
    </ul>
  </li>
  <li class="nav-item">
    <a class="nav-link" href="./taskforces.html" rel="" target="">
 <span class="menu-text">Task forces</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./ha.html" rel="" target="">
 <span class="menu-text">Health authority interactions</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./publications.html" rel="" target="">
 <span class="menu-text">Publications</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./code.html" rel="" target="">
 <span class="menu-text">Code</span></a>
  </li>  
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-events" role="button" data-bs-toggle="dropdown" aria-expanded="false" rel="" target="">
 <span class="menu-text">Events</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-events">    
        <li>
    <a class="dropdown-item" href="./events_upcoming.html" rel="" target="">
 <span class="dropdown-text">Upcoming events</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./events_past.html" rel="" target="">
 <span class="dropdown-text">Past events</span></a>
  </li>  
    </ul>
  </li>
  <li class="nav-item">
    <a class="nav-link" href="./news.html" rel="" target="">
 <span class="menu-text">Newsletters</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./resources.html" rel="" target="">
 <span class="menu-text">Further resources</span></a>
  </li>  
</ul>
            <div class="quarto-navbar-tools ms-auto">
</div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#context" id="toc-context" class="nav-link active" data-scroll-target="#context">Context</a></li>
  <li><a href="#why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" id="toc-why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" class="nav-link" data-scroll-target="#why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy">Why is censoring of subjects in the estimator for a time-to-event endpoint implementing a hypothetical strategy?</a></li>
  <li><a href="#what-are-other-estimators-of-a-hypothetical-estimand-strategy-than-simply-using-censoring" id="toc-what-are-other-estimators-of-a-hypothetical-estimand-strategy-than-simply-using-censoring" class="nav-link" data-scroll-target="#what-are-other-estimators-of-a-hypothetical-estimand-strategy-than-simply-using-censoring">What are other estimators of a hypothetical estimand strategy than simply using censoring?</a></li>
  <li><a href="#if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" id="toc-if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" class="nav-link" data-scroll-target="#if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd">If you censor treatment switches, are you somehow inducing non-random / non-independent censoring, especially in the context of external controls where cross-over is more limited in trials and switches are more common in RWD?</a></li>
  <li><a href="#for-an-endpoint-of-pfs-should-we-censor-at-start-of-new-anticancer-therapy-nact-before-progression-and-what-estimand-does-either-approach-estimate" id="toc-for-an-endpoint-of-pfs-should-we-censor-at-start-of-new-anticancer-therapy-nact-before-progression-and-what-estimand-does-either-approach-estimate" class="nav-link" data-scroll-target="#for-an-endpoint-of-pfs-should-we-censor-at-start-of-new-anticancer-therapy-nact-before-progression-and-what-estimand-does-either-approach-estimate">For an endpoint of PFS, should we censor at start of new anticancer therapy (NACT) before progression? And what estimand does either approach estimate?</a>
  <ul class="collapse">
  <li><a href="#context-1" id="toc-context-1" class="nav-link" data-scroll-target="#context-1">Context</a></li>
  <li><a href="#implicit-hypothetical-strategy" id="toc-implicit-hypothetical-strategy" class="nav-link" data-scroll-target="#implicit-hypothetical-strategy">(implicit) Hypothetical strategy</a></li>
  <li><a href="#implicit-treatment-policy-strategy" id="toc-implicit-treatment-policy-strategy" class="nav-link" data-scroll-target="#implicit-treatment-policy-strategy">(implicit) Treatment policy strategy</a></li>
  <li><a href="#recommendation" id="toc-recommendation" class="nav-link" data-scroll-target="#recommendation">Recommendation</a></li>
  <li><a href="#polarix-odac" id="toc-polarix-odac" class="nav-link" data-scroll-target="#polarix-odac">Polarix ODAC</a></li>
  </ul></li>
  <li><a href="#references" id="toc-references" class="nav-link" data-scroll-target="#references">References</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">New-anti lymphoma treatment (NALT) as intercurrent event for PFS in lymphoma</h1>
</div>


<div class="quarto-title-meta-author">
  <div class="quarto-title-meta-heading">Author</div>
  <div class="quarto-title-meta-heading">Affiliation</div>
  
    <div class="quarto-title-meta-contents">
    <p class="author">Estimands SME network </p>
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            PD Data and Statistical Sciences
          </p>
      </div>
    </div>

<div class="quarto-title-meta">

      
  
    
  </div>
  

</header>

<section id="context" class="level1">
<h1>Context</h1>
<p>In FDA interactions on several Roche trials ()</p>
</section>
<section id="why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" class="level1">
<h1>Why is censoring of subjects in the estimator for a time-to-event endpoint implementing a hypothetical strategy?</h1>
<p>Assume you have a trial with 100 patients and primary endpoint PFS. (In a frequentist world) This trial is a sample drawn from a metaphysical population, where the latter is our primary interest and one of the attributes of the estimand defintion. In the population PFS has a true survival function <span class="math inline">\(S\)</span>.</p>
<p>In a first scenario, assume you observe PFS for all the 100 patients. Then, an unbiased estimator <span class="math inline">\(\hat S_1\)</span>, such as e.g.&nbsp;Kaplan-Meier (which in this case is nothing else than 1 - CDF), estimates <span class="math inline">\(S\)</span>.</p>
<p>Now assume a second scenario where 20 patients are <strong>randomly censored</strong> (following the terminology in <a href="material/Unkel et al (2019) On estimands and the analysis of AE with varying FU times.pdf">Unkel et al. <span class="citation" data-cites="unkel_19">(<span><strong>unkel_19?</strong></span>)</span></a>, based on <span class="citation" data-cites="aalen_08">(<a href="#ref-aalen_08" role="doc-biblioref"><strong>aalen_08?</strong></a>)</span>). If we now estimate <span class="math inline">\(S\)</span> using an unbiased estimator <span class="math inline">\(\hat S_2\)</span>, e.g.&nbsp;Kaplan-Meier, again then we are “correctly” using the information of the 20 censored patients, i.e.&nbsp;for these 20 patients “…outcome after <span class="math inline">\(x\)</span> number of months is imputed by using the longer term outcomes of other patients in their treatment group who also are free of the outcome at <span class="math inline">\(x\)</span> number of months and remain under follow-up beyond <span class="math inline">\(x\)</span> number of months.” (terminology used in <a href="material/Fleming et al (2009) Issues in Using PFS When Evaluating Oncology Products.pdf">Fleming et al. <span class="citation" data-cites="fleming_09">(<span><strong>fleming_09?</strong></span>)</span></a>). So indeed, the estimand we are targeting (namely the function <span class="math inline">\(S\)</span>) remains the same as in the hypothetical world where censoring would not happen.</p>
<p>It is important to note that censoring alone is only sufficient for implementing a hypothetical strategy if censoring is, e.g., <strong>random</strong> in the sense described in, e.g., <a href="material/Unkel et al (2019) On estimands and the analysis of AE with varying FU times.pdf">Unkel et al. <span class="citation" data-cites="unkel_19">(<span><strong>unkel_19?</strong></span>)</span></a>. This is essentially equivalent to the “missing-at-random” assumption for longitudinal outcomes.</p>
</section>
<section id="what-are-other-estimators-of-a-hypothetical-estimand-strategy-than-simply-using-censoring" class="level1">
<h1>What are other estimators of a hypothetical estimand strategy than simply using censoring?</h1>
<p>Sometimes it might be plausible that subjects who discontinued treatment early would have done worse than those who did not, <strong>even in a hypothetical world where they had stayed on treatment</strong>. One method for imputing T2E endpoints in this case is the method by <a href="material/Jackson et al (2014) Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation.pdf">Jackson et al. <span class="citation" data-cites="jackson_14">(<span><strong>jackson_14?</strong></span>)</span></a> which is implemented in the <a href="https://cran.r-project.org/package=InformativeCensoring">InformativeCensoring</a> <a href="https://cran.r-project.org">R</a> package. At Roche, the Satralizumab team used this to answer EMA concerns about non-random / non-informative censoring in one of their trials, see <a href="BN40898.html">this case study</a> that also includes the original program code based on <a href="https://cran.r-project.org/package=InformativeCensoring">InformativeCensoring</a>.</p>
<p>Alternatively, <a href="https://pages.github.roche.com/estimand/estimand/docs/switching.html#inverse-probability-of-censoring-weights-ipcw">inverse-probability of censoring weights</a> (IPCW) has also been proposed. Here, patients who do not have the intercurrent event serve as proxies for those who do. For estimation we need covariates that make PFS and the intercurrent event conditionally independent. This has been used e.g.&nbsp;in the <a href="switching.html#inverse-probability-of-censoring-weights-ipcw">Polarix trial</a>.</p>
</section>
<section id="if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" class="level1">
<h1>If you censor treatment switches, are you somehow inducing non-random / non-independent censoring, especially in the context of external controls where cross-over is more limited in trials and switches are more common in RWD?</h1>
<p>Yes, generally treatment switches are often informative (which does not mean censoring is informative, see <a href="material/Andersen (2005, encyclopedia) Censored data.pdf">Andersen <span class="citation" data-cites="andersen_05">(<span><strong>andersen_05?</strong></span>)</span></a>) as people are switching because their current treatment is not working. However, you could also imagine some scenarios where the reason for switching may not carry information about a patient, e.g.&nbsp;a region may limit the availability of a certain treatment to a limited number of cycles for cost-effectiveness reasons.</p>
<p>Find more resources on treatment switching on this <a href="switching.html">dedicated page</a>.</p>
</section>
<section id="for-an-endpoint-of-pfs-should-we-censor-at-start-of-new-anticancer-therapy-nact-before-progression-and-what-estimand-does-either-approach-estimate" class="level1">
<h1>For an endpoint of PFS, should we censor at start of new anticancer therapy (NACT) before progression? And what estimand does either approach estimate?</h1>
<section id="context-1" class="level2">
<h2 class="anchored" data-anchor-id="context-1">Context</h2>
<p>For an endpoint of PFS, start of NACT before PD or death is an <strong>intercurrent event</strong>. The questions then are:</p>
<ul>
<li>Which of the five estimand strategies in the <a href="https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf">ICH E9 addendum</a> should we use?</li>
<li>How should we estimate the chosen estimand?</li>
</ul>
</section>
<section id="implicit-hypothetical-strategy" class="level2">
<h2 class="anchored" data-anchor-id="implicit-hypothetical-strategy">(implicit) Hypothetical strategy</h2>
<p>In the 00’s there was a lively debate whether one should censor at start of NACT in lymphoma indications, and this debates appears to go on until today. The FDA guidance <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"><em>Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics</em></a> <span class="citation" data-cites="fda_endpoints">(<a href="#ref-fda_endpoints" role="doc-biblioref"><strong>fda_endpoints?</strong></a>)</span> recommends to censor at date of “new anticancer treatment”. This is in line with <a href="material/Cheson et al (2007) Revised response criteria for malignant lymphoma.pdf">Cheson et al. <span class="citation" data-cites="cheson_07">(<span><strong>cheson_07?</strong></span>)</span></a> who writes</p>
<blockquote class="blockquote">
<p>…in studies in which failure to respond without progression is considered an indication for another therapy, such patients should be censored at that point for the progression analysis.</p>
</blockquote>
<p>This estimator, i.e.&nbsp;censoring at start of 2nd line therapy, corresponds to a <strong>hypothetical</strong> estimand. That the FDA is still recommending that approach is interesting, given the FDA’s reluctance to hypothetical estimands in general. For example, in <a href="papers/Ionan et al (2023), Clinical and Statistical Perspectives on the Estimand Framework Implementation.pdf">Ionan et al <span class="citation" data-cites="ionan_22">(<span>2022</span>)</span></a> (FDA 1st author, paper written together with industry statisticians)</p>
<blockquote class="blockquote">
<p>For example, in the case of a hypothetical strategy, it is necessary to describe precisely the nature of the hypothetical scenario under which estimation of treatment effect is of interest and why the actual scenario in which the intercurrent event occurs is problematic for the interpretation of the treatment effect. It is important to justify the relevance of the corresponding treatment effect to be estimated, and the statistical model that accurately captures the specific chosen hypothetical scenario.</p>
</blockquote>
<p>and</p>
<blockquote class="blockquote">
<p>The clinical and regulatory interest of such hypotheticals is limited and would usually depend on a clear understanding of why and how the intercurrent event, or its consequences, would be expected to be different in clinical practice than in the clinical trial.</p>
</blockquote>
<p>So, applied to NACT a hypothetical estimand corresponds to interest in a treatment effect in a world where <strong>such NACT would not exist!</strong> Typically, that seems not a plausible estimand.</p>
<p>Similarly, <a href="papers/Mayo and Kim (2023) What can be Achieved with the Estimand Framework.pdf">Mayo and Kim <span class="citation" data-cites="mayo_23">(<span><strong>mayo_23?</strong></span>)</span></a> (both FDA authors) discourage use of hypothetical estimands:</p>
<blockquote class="blockquote">
<p>More precisely defining the clinical question and corresponding estimand has led to some challenges and differences in perspectives. For example, it is uncommon that we have found a hypothetical strategy to be the most relevant one for the primary clinical question used in regulatory decision-making (with exceptions, e.g., a pandemic leading to temporary site closures that are not expected to occur in general clinical practice in the future).</p>
</blockquote>
</section>
<section id="implicit-treatment-policy-strategy" class="level2">
<h2 class="anchored" data-anchor-id="implicit-treatment-policy-strategy">(implicit) Treatment policy strategy</h2>
<p>Interestingly, in another highly cited paper by Fleming et al.&nbsp;<a href="material/Fleming et al (2009) Issues in Using PFS When Evaluating Oncology Products.pdf">Fleming et al. <span class="citation" data-cites="fleming_09">(<span><strong>fleming_09?</strong></span>)</span></a>, it is recommended that</p>
<blockquote class="blockquote">
<p>…patients should not be censored at the time other treatments are initiated when analyzing the PFS end point…</p>
</blockquote>
<p>This corresponds to a <strong>treatment policy</strong> estimand. This is also implicitly the recommendation in the EMA guidance <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using_en.pdf">Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man</a>:</p>
<blockquote class="blockquote">
<p>The time of the progression or recurrence event is determined using the first date when there is documented evidence that the criteria have been met, even in situations where progression is observed after one or more missed visits, treatment discontinuation, or <strong>new anti-cancer treatment</strong>.</p>
</blockquote>
<p>A treatment policy strategy for start of 2nd line therapy for an endpoint of PFS has, e.g., been implemented in:</p>
<ul>
<li>All pivotal Gazyva trials (Gadolin, Gallium, Goya).</li>
<li>All Phase 3 lung cancer trial at J&amp;J (informal communication, no public source available so far).</li>
<li>In a published Phase 2 oncology trial from Bayer: Search for “policy” in <a href="material/Kindler et al (2022) ARCS-M.pdf">Kindler et al. <span class="citation" data-cites="kindler_22">(<span><strong>kindler_22?</strong></span>)</span></a>.</li>
</ul>
</section>
<section id="recommendation" class="level2">
<h2 class="anchored" data-anchor-id="recommendation">Recommendation</h2>
<p>In general, we recommend to have the discussion “whether to censor or not” not on the estimator level, but rather discuss which estimand - hypothetical or treatment policy - we are interested in.</p>
<p>Given the above considerations it appears that a treatment policy estimand is typically what seems of most interest to decision makers.</p>
</section>
<section id="polarix-odac" class="level2">
<h2 class="anchored" data-anchor-id="polarix-odac">Polarix ODAC</h2>
<p>Whether to censor at NACT or not was actually a key question in the Polarix ODAC: <a href="https://glob.1sharepoint.roche.com/team/Roche-Stats-Workshop/Meetings/20230628_Yan_Rufibach_Polarix_estimand.pdf?d=w257a70c7592340e2bebb53bb06979973">slides</a> and <a href="https://streamingmedia.roche.com/media/Basel+Biostatistics+Community+Forum+%282023-06-28%29/1_pflao31k">recording</a> of a presentation by Mark Yan and Kaspar Rufibach to the Basel Biostatistics Community Forum on 28th June 2023.</p>
</section>
</section>
<section id="references" class="level1">




</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body hanging-indent" role="list">
<div id="ref-ionan_22" class="csl-entry" role="listitem">
Ionan, Alexei C., Miya Paterniti, Devan V. Mehrotra, John Scott, Bohdana Ratitch, Sylva Collins, Shanti Gomatam, Lei Nie, Kaspar Rufibach, and Frank Bretz. 2022. <span>“Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation.”</span> <em>Statistics in Biopharmaceutical Research</em> 0 (ja): 1–12. <a href="https://doi.org/10.1080/19466315.2022.2081601">https://doi.org/10.1080/19466315.2022.2081601</a>.
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>